Anticoagulation therapy is recommended for patients with non-valvular atrial fibrillation
(NVAF) and an increased risk of stroke. Although apixaban showed superiority over warfarin …

Background: Guidelines caution against the use of non–vitamin K antagonist oral
anticoagulants in patients with extremely high (> 120 kg) or low (≤ 60 kg) body weight …

Real-world studies have evaluated the use of anticoagulants in obese patients with
nonvalvular atrial fibrillation (NVAF), but they have been limited by sample size or the use of …

This ARISTOPHANES analysis examined stroke/systemic embolism (SE) and major
bleeding (MB) among a subgroup of nonvalvular atrial fibrillation (NVAF) patients with …

Atrial fibrillation (AF) is associated with increased risk of stroke and mortality. Prevention of
thromboembolism is the foundation of managing this common disease. 1 The nonvitamin K …

Background The benefit of apixaban to reduce stroke risk in morbidly obese patients with
nonvalvular atrial fibrillation (AF) is still undetermined. The International Society of …

Background Obese patients are underrepresented in clinical trials assessing the
comparative effectiveness and safety of use of direct oral anticoagulants vs use in atrial …

Background: Contemporary guidelines for managing nonvalvular atrial fibrillation (NVAF)
include apixaban and rivaroxaban as first-line anticoagulation treatment options. Minimal …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Background Recent guidelines recommend using direct oral anticoagulants (DOACs) as first-
line agents in patients with non-valvular atrial fibrillation (NVAF). Research is currently …